Bicara Therapeutics (BCAX) announced the first patients have been enrolled in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in first line recurrent/metastatic head and neck squamous cell carcinoma. Ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX: